Joshua D. Vardigan

The novel phosphodiesterase 10A inhibitor THPP-1 has antipsychotic-like effects in rat and improves cognition in rat and rhesus monkey

Sean M. Smith, Jason M. Uslaner, Christopher D. Cox et al. · Neuropharmacology · 2012 · 84 citations · Full text

Inhibitor Thpp-1, Novel Phosphodiesterase 10A, Behavioral Neuroscience +11

MK-801 produces a deficit in sucrose preference that is reversed by clozapine, d-serine, and the metabotropic glutamate 5 receptor positive allosteric modulator CDPPB: Relevance to negative symptoms associated with schizophrenia?

Joshua D. Vardigan, Sarah L. Huszar, Caitlyn McNaughton et al. · Pharmacology Biochemistry and Behavior · 2010 · 77 citations

Neuropsychology, Psychiatry, Sucrose Preference +13

Improved cognition without adverse effects: novel M1 muscarinic potentiator compares favorably to donepezil and xanomeline in rhesus monkey

Joshua D. Vardigan, Christopher E. Cannon, Vanita Puri et al. · Psychopharmacology · 2014 · 61 citations

Cognitive Science, Neurophysiology, Medicine +10

Aging African green monkeys manifest transcriptional, pathological, and cognitive hallmarks of human Alzheimer's disease

Paige E. Cramer, Renee C. Gentzel, Keith Q. Tanis et al. · Neurobiology of Aging · 2017 · 53 citations

Cognitive Hallmarks, Alzheimer's Disease, Aging +9

The Selective Phosphodiesterase 9 (PDE9) Inhibitor PF-04447943 Attenuates a Scopolamine-Induced Deficit in a Novel Rodent Attention Task

Joshua D. Vardigan, Antonella Converso, Pete H. Hutson et al. · Journal of Neurogenetics · 2011 · 52 citations

Neuropsychology, Scopolamine-induced Deficit, Neurotransmitter +22